In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Assessment of Treatment Response in IDH-mutant Gliomas by Quantification of 2-Hydroxyglutarate with in-vivo 3D Magnetic Resonance Spectroscopy

    Final Number:
    194

    Authors:
    Franziska Loebel MD; Daniel P. Cahill MD; Wolfgang Bogner PhD; Malgorzata Marjanska; Elizabeth Gerstner; Tracy Batchelor MD; Bruce R Rosen; Andrew S Chi MD; Ovidiu C Andronesi

    Study Design:
    Laboratory Investigation

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2014 Annual Meeting

    Introduction: Mutations in isocitrate dehydrogenase (IDH) - present in a distinct subset of human gliomas characterized by younger age and improved prognosis- cause a marked elevation of the metabolite 2-hydroxyglutarate (2HG)[1,2]. This excess production of 2HG represents an ideal biomarker for these gliomas and can be measured with in-vivo magnetic resonance spectroscopy [3]. We previously demonstrated that 2HG can be detected reliably in IDH-mutant gliomas with 3D spectral-edited MR spectroscopic imaging (MRSI) [4]. Here, we aimed to show that 3D metabolomic mapping of 2HG can be utilized to evaluate treatment response in IDH-mutant gliomas.

    Methods: 3D metabolomic maps were measured in 18 IDH-mutant glioma patients prior to adjuvant radiation or chemotherapy with a robust and efficient 3D MRSI sequence. All measurements were performed with a whole-body 3T MR scanner (Siemens Tim Trio with VB17 software). Spectra were fitted with LCModel software. All patients with detectable levels of 2HG in the baseline scan were subjected to a post-treatment 3D MRSI to measure changes of 2HG-levels after adjuvant therapy.

    Results: 16 of 18 patients (88.9%) demonstrated detectable levels of 2HG on their baseline scan. Matched pre- and post-treatment 3D metabolomic maps indicated varying response to treatment: 4 patients demonstrated significant reduction of 2HG intensities after radiation therapy (Fig 1), while the remaining patients demonstrated mixed response (partial reduction of 2HG) to adjuvant treatment.

    Conclusions: Assessment of treatment response is feasible with in-vivo 3D MRSI of 2HG in IDH-mutant glioma patients. Significant reduction of 2HG-levels in patients after completion of radiotherapy is suggestive of positive response to treatment. Further validation and longitudinal quantification of 2HG in IDH-mutant gliomas with 3D MRSI is needed to evaluate the ability of the presented approach to reliably determine treatment response. Nevertheless, this non-invasive method yields great potential for clinical applicability and could tremendously improve the management of IDH-mutant glioma patients.

    Patient Care: Longitudinal non-invasive monitoring of 2HG could improve the management of IDH-mutant glioma patients by indicating treatment response and distinguishing treatment effects from progression or tumor recurrence.

    Learning Objectives: By the conclusion of this session, participants should be able to describe different methods for in-vivo spectroscopic assessment of 2HG in IDH-mutant gliomas and evaluate treatment responses in patients using 3D metabolomic maps.

    References: [1] Parsons DW et al. , Science 2008; 321:1807-12., [2] Yan H et al., N Engl J Med 2009; 360(8):765-73., [] [3] Dang L et al., Nature 2009; 462:739-52., [4] Andronesi OC et al., STM 2012; 4:116ra114.,

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy